Time: 10:00 - 12:00 UK time Presenters: Jessica Purchase, Group Health Economics Manager (F. Hoffmann-La Roche Ltd, Welwyn) and Monica Daigl, HTA Statistician and Health Economist (F. Hoffmann-La Roche Ltd, Basel)
There is a simple equation for access in the UK: Access = Reimbursement + Uptake
Yet, whilst a simple and logical approach, each component is challenging to achieve.
This webinar focuses on the National Reimbursement side: the National Institute for Health and Care Excellence (NICE) - who they are, what is involved in the Health Technology Appraisal (HTA) assessment, how they make decisions.
We’ll also review where the devolved nations come in: how do the Scottish Medicines Consortium (SMC) and All Wales Medicines Strategy Group (AWMSG) differ from NICE in decision making?
Finally, through the use of a real world example, we’ll explore the key drivers and barriers experienced in decision making: specifically the challenges associated with correct comparators and predicting of long term outcomes.
This will lead to the second part of the webinar. We will focus on two advanced statistical techniques to inform health economic models: modelling of time to event endpoints such as progression free and overall survival beyond the duration of a clinical study to predict long-term outcomes; and network meta analyses to estimate the value of a drug in the absence of direct comparative evidence.
Finally, we provide our key recommendations for the future of clinical trial design, to support access for the UK market.
About the Presenters:
Jessica Purchase is a Group Health Economics Manager in the Health Economics and Strategic Pricing team in Roche UK. She joined Roche in 2016, following 5 years of Health Economics and Market Access consulting. In her role she has successfully lead on a variety of HTAs resulting in UK access in the oncology space.
Monica Daigl is a medical statistician and epidemiologist with >15 years of experience in the analysis of clinical trials and observational studies in pharma, medical device industry and academia. She joined 2014 the Global Access Center of Excellence at F. Hoffmann-La Roche as HTA Statistician and Health Economist. In her role she supports Roche affiliates with their local HTA submissions in multiple therapeutic areas.
£20 (plus VAT)
Registration has now closed.
Joint PSI, EFSPI & ASA BIOP Webinar: Estimands
PSI, the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) and the Biopharmaceutical Section of the American Statistical Association (ASA) are jointly organising a webinar on Estimands in Practice. Speakers from regulatory authorities (FDA and EMA) and industry will present on their experience on this topic to date.
Discover your potential by working as a Covance Senior Principal / Principal Biostatistician. You'll enjoy a varied role working for different sponsors across several therapeutic areas, leading projects and mentoring junior members of the department.
Biometrics at AstraZeneca provides the data that influences decisions on how we roll back the frontiers of science to bring life-changing medicines to the world. We are at the heart of design, analytics and interpretation of AstraZeneca’s portfolio.